Indication: Alzheimer’s Disease
Title: : Efficacy, Safety and Tolerability of AVP-786 (Deuterated [d6]-Dextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type
Purpose: Patients with agitation secondary to dementia of the Alzheimer’s type. The diagnosis of probable Alzheimer’s disease will be based on the ‘2011 Diagnostic Guidelines for Alzheimer’s Disease’ issued by the National Institute on Aging (NIA)-Alzheimer’s Association (AA) workgroups.
For details go to Clinical Trials.gov
Indication: Alzheimer’s Disease
Title: CREAD Study” A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer’s Disease (AD)
Purpose: This randomized, double-blind, placebo-controlled, parallel group study will evaluate the efficacy and safety of crenezumab versus placebo in participants with prodromal to mild AD. Participants will be randomized 1:1 to receive either intravenous (IV) infusion of crenezumab or placebo every 4 weeks (q4w) for 100 weeks. The final efficacy and safety assessment will be performed 52 weeks after the last crenezumab dose.
For details go to Clinical Trials.gov